Prevention of Myopia onset using ultra-low dose atropine. (PRE-MYO Study)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006883

Enrollment

Unknown

Registered

2015-08-06

Start date

2015-08-14

Completion date

Unknown

Last updated

2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atropine, myopia

Interventions

Three groups:0.01% atropine both eyes once daily versus 0.05% atropine versus lubricant eye drops once daily.

Eligibility

Sex/Gender

All

Age

4 Years to 9 Years

Inclusion criteria

Inclusion criteria: 1. Aged 4 to 9 years; 2. Myopia: SE > -1.0D and < +1.0 D; 3. Astigmatism: < 1 D; 4. Informed parental consent.

Exclusion criteria

Exclusion criteria: 1. Ophthalmic diseases Refractive errors: SE +1.0 D; 2. Previous use of treatment of atropine; 3. Allergy or intolerance to atropine; 4. Inability to attend regular follow up assessment.

Design outcomes

Primary

Measure	Time frame
Proportion of onset of myopia and proportion of fast myopia progressor in each group.;	—

Secondary

Measure	Time frame
Myopic progression is measured by change in spherical equivalent refraction (SER).;Cycloplegic refraction is assessed by using an auto-refractometer.;Eyeball growth is measured by change in axial length, using the IOL master.;	—

Countries

China

Contacts

Public ContactDr. YAM Cheuk Sing Jason

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

yamcheuksing@gmail.com+852 39435833

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026